Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRI-beva and HCQ in DTP-Selected mCRC
NCT05843188Phase 2Active, not recruiting
- Sponsor
- University Health Network
- Start
- Aug 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of hydroxychloroquine in colorectal cancer (CRC) (2 arms), sponsored by University Health Network. Primary endpoint: Overall Response Rate at 48 months. Started Aug 2023; status: active, not recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05843188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05843188.